Across TCGA pan-cancer cohorts, ATP10D mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated ATP10D data layer compared with 22 for mass-spec protein and 10 for mutation status.
The strongest signal is observed in lung adenocarcinoma (LUAD), where higher ATP10D mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated ATP10D expression acts as an unfavorable survival marker.
LUAD and GBM are the cancer types where ATP10D mass-spec protein most reproducibly stratifies survival.